Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma (EVOLITION)

Gustave Roussy

Status: Enrolling

Conditions: Follicular Lymphoma; Diffuse Large B-Cell Lymphoma

Treatments: Biological: blood sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT06813573

2023-3670 (Other Identifier)

2023-A02716-39

Details and patient eligibility

About

The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically proven diagnosis of diffuse large B cell lymphoma or follicular lymphoma, according to the WHO 2016 classification, requiring a first line of treatment with a RCHOP 21 regimen
• Agreement to participate after receiving oral and written information on the study

Exclusion criteria

• History of previous treatment for lymphoma (excluding localized low dose radiotherapy in the case of follicular lymphoma)
• Treatment with a chemotherapy regimen different from RCHOP21

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Patients receiving first line of treatment with a RCHOP 21 regimen

Experimental group

Description:

All patients will receive first line of treatment with a RCHOP 21 regimen

Treatment:

Biological: blood sampling